Synvisc One 6ml

Osteoarthritis remains one of the most frequently diagnosed degenerative joint conditions worldwide, particularly affecting adults over the age of 45. It is characterized by the progressive breakdown of cartilage, reduced synovial fluid quality, and increasing friction within the joint space, which eventually leads to knee pain. Over time, these changes lead to pain, stiffness, swelling, and a gradual reduction in mobility. The knee joint is among the most commonly affected areas, often resulting in significant impairment in daily movement and quality of life.

Although osteoarthritis cannot currently be reversed, its symptoms can be managed effectively through a combination of lifestyle adjustments, pharmacological therapies, and intra-articular treatments. Among the most established medical options for patients who do not respond sufficiently to oral analgesics or conservative approaches to treat knee pain is viscosupplementation therapy. One of the most recognized products in this category is Synvisc One 6 ml, a single-injection hyaluronic acid-based solution designed to restore joint lubrication and improve function in osteoarthritic knees.

A SIDE NOTE
DKdermal supplies authentic, professional-grade cosmetic and medical injectables, including Synvisc One, exclusively to licensed healthcare providers.

General Information

Synvisc One is an intra-articular injectable treatment formulated to mimic and supplement the natural synovial fluid present in healthy joints. Its primary role is to improve the viscoelastic properties of joint fluid, thereby reducing friction between cartilage surfaces and enhancing shock absorption during movement.

The product is specifically indicated for knee osteoarthritis and is designed as a single-dose regimen, containing 6 ml of sterile solution in a prefilled syringe. This allows for a complete treatment in one administration session, unlike earlier multi-injection hyaluronic acid therapies.

Synvisc One is manufactured by Sanofi, a globally recognized pharmaceutical company known for producing a wide range of prescription therapies and biologics used in clinical practice worldwide.

A SIDE NOTE
The Synvisc One treatment works by restoring the elasticity and viscosity within the joint allowing a broader movement. Also, it reduces inflammation caused by arthritis by simulating the work of hyaluronic acid natural found in human body.

Composition (Hylan G-F 20 & Other Ingredients)

The formulation is based on hylan G-F 20, a modified derivative of hyaluronan. This compound is chemically cross-linked to increase its molecular weight and residence time within the joint space. The result is a substance that more closely resembles the mechanical and protective characteristics of natural synovial fluid under healthy conditions.

In addition to hylan polymers, the solution contains physiological sodium chloride components, which help maintain isotonic balance and ensure compatibility with the intra-articular environment. These excipients support stability and optimize the physical properties of the final injectable formulation. Also, Synvisc One includes disodium hydrogen phosphate, sodium dihydrogen phosphate hydrate, and water.

Mechanism of Action

In osteoarthritic joints, synovial fluid becomes thinner and less effective at cushioning mechanical stress. This leads to increased wear on cartilage surfaces and heightened pain during movement. Synvisc One functions by supplementing this depleted fluid with a high-viscosity hyaluronic acid derivative.

Once injected into the knee joint, the hylan-based solution acts as both a lubricant and a shock absorber used to treat pain associated with osteoarthritis. It helps reduce friction during motion and may improve joint mechanics over time. While it does not regenerate cartilage, it creates a more favorable environment for joint movement, which can significantly reduce discomfort in appropriately selected patients.

The effects are typically gradual rather than immediate, as the product integrates into the synovial space and modifies the biomechanical behavior of the joint over several days following administration.

Indications to Inject Synvisc One 6ml

Synvisc One is an osteoarthritis treatment intended for patients diagnosed with knee osteoarthritis, particularly those experiencing moderate to severe reactions that have not been adequately managed through non-invasive therapies. It is commonly considered when:

• Oral pain relievers (for instance, simple analgesics) or anti-inflammatory medications provide insufficient relief;
• Conservative nonpharmacologic therapy (for instance, physical therapy) and lifestyle modifications alone are not enough to maintain mobility;
• Patients fail to respond adequately to non-invasive treatments and are seeking an alternative intervention to manage chronic joint pain.

Healthcare professionals may recommend Synvisc One as part of a broader osteoarthritis management plan aimed at improving functional capacity and reducing reliance on systemic medications.

Administration

Synvisc One is a single dose treatment strictly intended for administration by qualified healthcare professionals trained in intra-articular injection techniques that do not affect blood vessels. The product is injected directly into the knee joint cavity under aseptic conditions.

Because it is supplied as a single prefilled 6 ml syringe, the entire dose is administered in one session, typically into the affected knee. This simplifies treatment logistics and improves patient compliance compared to multi-injection protocols.

In some clinical settings, a local anesthetic may be applied prior to injection to enhance patient comfort, although lidocaine is not included in the formulation itself.

A SIDE NOTE
It is important not to use disinfectants containing ammonium salts before the administration of Synvisc One 6ml.

Contraindications and Precautions

While Synvisc One is generally well tolerated, it is not appropriate for all patients. Certain conditions and clinical scenarios may contraindicate its use. Administration should be avoided in individuals with:

• Known hypersensitivity to hylan G-F 20 or hyaluronic acid derivatives (namely, patients with known avian allergies should not use Synvisc One due to its derivation from rooster combs);
• Active infection or skin disease near the intended injection site;
• Severe systemic infections or uncontrolled inflammatory conditions;
• History of allergic reactions to avian proteins, since the product is derived from materials linked to avian sources during manufacturing processes.

Caution is also advised in patients with complex comorbidities, particularly those involving immune system disorders. Synvisc One is not recommended for use during pregnancy or breastfeeding due to limited clinical data in these populations. Additionally, its use in pediatric patients is generally not indicated.

Healthcare providers are encouraged to conduct a thorough patient assessment prior to administration to ensure suitability.

Possible Side Effects

As with most intra-articular therapies, Synvisc One may be associated with localized adverse effects following injection. Such reactions are typically mild and transient.

Common side effects of Synvisc One include swelling, pain, or irritation at the injection site, which usually resolve within 48 hours. Also, reported post-injection responses may include:

• Temporary tenderness at the injection site;
• Joint effusion;
• Sensation of warmth or stiffness in the treated knee;
• Short-term fluid accumulation within the joint;
• And other side effects.

In most cases, these symptoms (especially minor side effects) resolve spontaneously within a few days without the need for additional medical intervention. Serious systemic adverse reactions that require attention of a doctor immediately are uncommon when the product is administered correctly.

A SAFETY NOTE
Patients should seek immediate medical attention if they experience signs of hypersensitivity or allergic reactions after receiving Synvisc One.

Expected Results

Clinical experience suggests that the therapeutic effects of Synvisc One may last for up to six months following a single injection. However, individual outcomes vary depending on factors such as disease severity, activity level, body weight, and overall joint health.

Some patients may require repeat treatments to allow more extensive movements after symptom recurrence. The timing of subsequent injections is determined by the treating healthcare provider based on clinical response and symptom progression.

A SIDE NOTE
A single course of Synvisc injections can last up to 52 weeks according to prospective clinical data, but the manufacturer specifies that results typically last up to six months.

Post-Injection Recommendations

Following the administration of a Synvisc One injection, patients are generally advised to take certain precautions to optimize outcomes and minimize temporary discomfort. These may include:

• Limiting high-impact or strenuous physical activity for a short period (namely, patients should avoid strenuous or high-impact activities for at least 2 days after receiving a Synvisc One injection to minimize side effects);
• Avoiding prolonged standing or excessive weight-bearing on the treated knee immediately after injection;
• Refraining from applying irritant substances or incompatible topical agents at the injection site;
• Using intermittent cold compresses if mild swelling or discomfort occurs.

Most individuals can gradually resume normal daily activities shortly after treatment, depending on their physician’s guidance.

Buy Synvisc One 6ml at DKdermal

A viscosupplement injection of Synvisc One 6 ml represents a well-established viscosupplementation therapy designed to support patients suffering from knee osteoarthritis. By enhancing synovial fluid function and improving joint lubrication, it offers a practical, minimally invasive option for the relief of factors causing pain in appropriately selected cases.

DKdermal offers Synvisc One 6 ml and other professional injectable treatments at reasonable prices to licensed practitioners. The platform focuses on delivering authentic products sourced through compliant distribution channels, ensuring reliability for clinical environments. Order today to take advantage of a quick purchasing process, consistent product availability, and beneficial wholesale discounts.

A SIDE NOTE
It is legal to order Synvisc One from international distributors online. However, please make sure to rely on a trustworthy supplier to ensure the authenticity and quality of the purchased product. Also, please note that at some stores (including DKdermal), bulk purchases of Synvisc One can lead to lower prices per unit, with discounts available for larger orders.